$10.42
+0.78 (+8.09%)
Open$9.65
Previous Close$9.64
Day High$10.60
Day Low$9.26
52W High$15.57
52W Low$5.60
Volume—
Avg Volume405.2K
Market Cap262.67M
P/E Ratio—
EPS$-5.80
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+290.2% upside
Current
$10.42
$10.42
Target
$40.66
$40.66
$22.44
$40.66 avg
$45.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.08M | 10.50M | 132.93M |
| Net Income | -143,547,561 | -440,329,941 | 3.48M |
| Profit Margin | -4,658.6% | -4,425.7% | 2.6% |
| EBITDA | -154,721,083 | -500,971,468 | 5.52M |
| Free Cash Flow | — | — | 2.68M |
| Rev Growth | -70.7% | -70.7% | -1.8% |
| Debt/Equity | 0.28 | 0.28 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |